Annabel Samimy
Stock Analyst at Stifel
(4.43)
# 314
Out of 5,106 analysts
59
Total ratings
48.15%
Success rate
34.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Annabel Samimy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TRVI Trevi Therapeutics | Maintains: Buy | $15 → $18 | $12.82 | +40.41% | 1 | Dec 19, 2025 | |
| SUPN Supernus Pharmaceuticals | Maintains: Hold | $50 → $55 | $51.71 | +6.36% | 8 | Dec 19, 2025 | |
| RGNX REGENXBIO | Maintains: Buy | $40 → $45 | $14.35 | +213.59% | 3 | Dec 19, 2025 | |
| OCS Oculis Holding AG | Maintains: Buy | $35 → $40 | $20.48 | +95.31% | 2 | Dec 19, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Buy | $45 → $52 | $37.35 | +39.22% | 2 | Dec 19, 2025 | |
| MBX MBX Biosciences | Maintains: Buy | $45 → $50 | $32.20 | +55.28% | 2 | Dec 19, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $55 → $48 | $24.82 | +93.39% | 4 | Dec 19, 2025 | |
| LGND Ligand Pharmaceuticals | Maintains: Buy | $220 → $230 | $197.37 | +16.53% | 2 | Dec 10, 2025 | |
| GPCR Structure Therapeutics | Maintains: Buy | $50 → $90 | $71.29 | +26.24% | 2 | Dec 9, 2025 | |
| PVLA Palvella Therapeutics | Maintains: Buy | $87 → $145 | $100.27 | +44.61% | 3 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $4.00 | +350.00% | 1 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $17 | $4.38 | +288.13% | 4 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $7.07 | +154.60% | 1 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $17.25 | +39.13% | 1 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $80 | $36.41 | +119.72% | 6 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $225 → $230 | $169.47 | +35.72% | 8 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 → $25 | $6.81 | +267.11% | 1 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $700 → $275 | $8.43 | +3,162.16% | 4 | Jun 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $1.47 | +1,532.65% | 1 | Aug 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $700 → $750 | $1.64 | +45,631.71% | 3 | Apr 16, 2020 |
Trevi Therapeutics
Dec 19, 2025
Maintains: Buy
Price Target: $15 → $18
Current: $12.82
Upside: +40.41%
Supernus Pharmaceuticals
Dec 19, 2025
Maintains: Hold
Price Target: $50 → $55
Current: $51.71
Upside: +6.36%
REGENXBIO
Dec 19, 2025
Maintains: Buy
Price Target: $40 → $45
Current: $14.35
Upside: +213.59%
Oculis Holding AG
Dec 19, 2025
Maintains: Buy
Price Target: $35 → $40
Current: $20.48
Upside: +95.31%
Mineralys Therapeutics
Dec 19, 2025
Maintains: Buy
Price Target: $45 → $52
Current: $37.35
Upside: +39.22%
MBX Biosciences
Dec 19, 2025
Maintains: Buy
Price Target: $45 → $50
Current: $32.20
Upside: +55.28%
Apellis Pharmaceuticals
Dec 19, 2025
Maintains: Buy
Price Target: $55 → $48
Current: $24.82
Upside: +93.39%
Ligand Pharmaceuticals
Dec 10, 2025
Maintains: Buy
Price Target: $220 → $230
Current: $197.37
Upside: +16.53%
Structure Therapeutics
Dec 9, 2025
Maintains: Buy
Price Target: $50 → $90
Current: $71.29
Upside: +26.24%
Palvella Therapeutics
Nov 24, 2025
Maintains: Buy
Price Target: $87 → $145
Current: $100.27
Upside: +44.61%
Jan 8, 2025
Initiates: Buy
Price Target: $18
Current: $4.00
Upside: +350.00%
Nov 22, 2024
Maintains: Buy
Price Target: $20 → $17
Current: $4.38
Upside: +288.13%
Jul 3, 2024
Initiates: Buy
Price Target: $18
Current: $7.07
Upside: +154.60%
May 3, 2024
Initiates: Buy
Price Target: $24
Current: $17.25
Upside: +39.13%
Mar 15, 2024
Reiterates: Buy
Price Target: $80
Current: $36.41
Upside: +119.72%
Mar 15, 2024
Maintains: Buy
Price Target: $225 → $230
Current: $169.47
Upside: +35.72%
Mar 8, 2024
Reiterates: Buy
Price Target: $23 → $25
Current: $6.81
Upside: +267.11%
Jun 26, 2023
Downgrades: Hold
Price Target: $700 → $275
Current: $8.43
Upside: +3,162.16%
Aug 24, 2021
Initiates: Buy
Price Target: $24
Current: $1.47
Upside: +1,532.65%
Apr 16, 2020
Maintains: Buy
Price Target: $700 → $750
Current: $1.64
Upside: +45,631.71%